Prognostic role of plasma vitamin D and its association with disease characteristics in germ cell tumours
Copyright © 2023 Lesko, Vlkova, Kalavska, De Angelis, Novotna, Obertova, Orszaghova, Palacka, Rejlekova, Sycova-Mila, Kollarik, Aziri, Pindak, Mardiak, Chovanec, Celec and Mego..
Background: Testicular cancer is the most common malignancy among young men. Vitamin D has pluripotent effects on cancer pathogenesis and plays a role in the metastatic cascade. The aim of this study is to analyze plasma vitamin D in association with clinico-pathological findings and prognosis in patients with germ-cell tumors (GCTs).
Methods: This study included 120 newly diagnosed and/or relapsed GCT patients treated from April 2013 to July 2020, for whom plasma was available in the biobank. Blood samples were drawn the 1st chemotherapy cycle as well as before the 2nd cycle. Plasma vitamin D was measured using ELISA and correlated with disease characteristics and the outcome. For survival analysis, the cohort was dichotomized into "low" and "high" based on median vitamin D.
Results: There was no significant difference in vitamin D plasma levels between healthy donors and GCT patients (p = 0.71). Vitamin D level was not associated with disease characteristics except for brain metastases, where patients with brain metastases had a vitamin D level that was 32% lower compared to patients without brain metastases, p = 0.03. Vitamin D was also associated with response to chemotherapy, with an approximately 32% lower value in patients with an unfavorable response compared to a favorable response, p = 0.02. Moreover, low plasma levels of vitamin D were significantly associated with disease recurrence and inferior progression-free survival (PFS), but not with overall survival (OS) (HR = 3.02, 95% CI 1.36-6.71, p = 0.01 for PFS and HR = 2.06, 95% CI 0.84-5.06, p = 0.14 for OS, respectively).
Conclusion: Our study suggests the prognostic value of pretreatment vitamin D concentrations in GCT patients. Low plasma vitamin D was associated with an unfavorable response to therapy and disease recurrence. However, it remains to be determined whether the biology of the disease confirms a causative role for low vitamin D and whether its supplementation affects the outcome.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Frontiers in oncology - 13(2023) vom: 21., Seite 1149432 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lesko, Peter [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cholecalciferol |
|---|
| Anmerkungen: |
Date Revised 30.04.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fonc.2023.1149432 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356177181 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356177181 | ||
| 003 | DE-627 | ||
| 005 | 20231226210313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2023.1149432 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1187.xml |
| 035 | |a (DE-627)NLM356177181 | ||
| 035 | |a (NLM)37114140 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lesko, Peter |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Prognostic role of plasma vitamin D and its association with disease characteristics in germ cell tumours |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.04.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2023 Lesko, Vlkova, Kalavska, De Angelis, Novotna, Obertova, Orszaghova, Palacka, Rejlekova, Sycova-Mila, Kollarik, Aziri, Pindak, Mardiak, Chovanec, Celec and Mego. | ||
| 520 | |a Background: Testicular cancer is the most common malignancy among young men. Vitamin D has pluripotent effects on cancer pathogenesis and plays a role in the metastatic cascade. The aim of this study is to analyze plasma vitamin D in association with clinico-pathological findings and prognosis in patients with germ-cell tumors (GCTs) | ||
| 520 | |a Methods: This study included 120 newly diagnosed and/or relapsed GCT patients treated from April 2013 to July 2020, for whom plasma was available in the biobank. Blood samples were drawn the 1st chemotherapy cycle as well as before the 2nd cycle. Plasma vitamin D was measured using ELISA and correlated with disease characteristics and the outcome. For survival analysis, the cohort was dichotomized into "low" and "high" based on median vitamin D | ||
| 520 | |a Results: There was no significant difference in vitamin D plasma levels between healthy donors and GCT patients (p = 0.71). Vitamin D level was not associated with disease characteristics except for brain metastases, where patients with brain metastases had a vitamin D level that was 32% lower compared to patients without brain metastases, p = 0.03. Vitamin D was also associated with response to chemotherapy, with an approximately 32% lower value in patients with an unfavorable response compared to a favorable response, p = 0.02. Moreover, low plasma levels of vitamin D were significantly associated with disease recurrence and inferior progression-free survival (PFS), but not with overall survival (OS) (HR = 3.02, 95% CI 1.36-6.71, p = 0.01 for PFS and HR = 2.06, 95% CI 0.84-5.06, p = 0.14 for OS, respectively) | ||
| 520 | |a Conclusion: Our study suggests the prognostic value of pretreatment vitamin D concentrations in GCT patients. Low plasma vitamin D was associated with an unfavorable response to therapy and disease recurrence. However, it remains to be determined whether the biology of the disease confirms a causative role for low vitamin D and whether its supplementation affects the outcome | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cholecalciferol | |
| 650 | 4 | |a germ cell tumor | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a prognostic biomarker | |
| 650 | 4 | |a progression-free survival | |
| 700 | 1 | |a Vlkova, Barbora |e verfasserin |4 aut | |
| 700 | 1 | |a Kalavska, Katarina |e verfasserin |4 aut | |
| 700 | 1 | |a De Angelis, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a Novotna, Vera |e verfasserin |4 aut | |
| 700 | 1 | |a Obertova, Jana |e verfasserin |4 aut | |
| 700 | 1 | |a Orszaghova, Zuzana |e verfasserin |4 aut | |
| 700 | 1 | |a Palacka, Patrik |e verfasserin |4 aut | |
| 700 | 1 | |a Rejlekova, Katarina |e verfasserin |4 aut | |
| 700 | 1 | |a Sycova-Mila, Zuzana |e verfasserin |4 aut | |
| 700 | 1 | |a Kollarik, Boris |e verfasserin |4 aut | |
| 700 | 1 | |a Aziri, Ramadan |e verfasserin |4 aut | |
| 700 | 1 | |a Pindak, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Mardiak, Jozef |e verfasserin |4 aut | |
| 700 | 1 | |a Chovanec, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Celec, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Mego, Michal |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d 2011 |g 13(2023) vom: 21., Seite 1149432 |w (DE-627)NLM218189583 |x 2234-943X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g day:21 |g pages:1149432 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fonc.2023.1149432 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |b 21 |h 1149432 | ||